1Dhir R,Vietmeier B,Arlotti J,et al.Early identification of individuals with prostate cancer in negative biopsies[J].J Urol,2004,171(4):1419-1423.
2Lehrer S,Diamond EJ,Mamkine B,et al.C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer[J].BJU Int,2005,95(7):961-962.
3Ekwere PD,Egbe SN.The changing pattern of prostate cancer in Nigerians:current status in the southeastern states[J].J Natl Med Assoc,2002,94(7):619-627.
4Marchal C,Redondo M,Padilla M,et al.Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].Histol Histopathol,2004,19(3):715-718.
5Mitsiades CS,Lembessis P,Sourla A,et al.Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer[J].Clin Exp Metastasis,2004,21(6):495-505.
6Shariat SF,Roudier MP,Wilcox GE,et al.Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes[J].Cancer Res,2003,63(15):4662-4670.
8Wu HH,Lapkus O,Corbin M.Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies[J].Appl Immunohistochem Mol Morphol,2004,12(4):285-289.
9Cerovic SJ,Brajuskovic GR,Vukotic-Maletic VD,et al.Neuroendocrine differentiation in prostate cancer[J].Vojnosanit Pregl,2004,61(5):513-518.
10Taftachi R,Ayhan A,Ekici S,et al.Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy:a comparison of PCNA and Ki-67[J].BJU Int,2005,95(4):650-654.
同被引文献10
1Eble JN, Sauter G, Epstein JI, et al. World Health Organization (WHO) classifications for tumours. Pathology and genetics of tumours of the urinary system and male genital organs [M]. IARC Press, 2004:162-162.
2Overstreet K, Haghighi P. Urothelial and prostate carcinoma metastasizing to the same lymph node [J]. Arch Pathol Lab Med, 2001, 125(10):1354.
3Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma [J]. Mod Pathol, 2000, 13(11):1186.
4Varma M, Morgan M, Amin MB, et al. High molecular weight cytokeratin antibody (clone 3413E12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer [J]. Histopathology, 2003, 42(2):167.
5Bassily NH, Vallorosi CJ, Akdas G, et al. Coordinate expression of cytokeratins7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma [J]. Am J Clin Pathol, 2000, 113(3):383.
6Oliai B, Kuhane H, Epstein JI, et al. A clinieopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy [J].Am J Surg Pathol, 2001, 25(6):794.
7Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores [J]. Am J Clin Pathol, 2002, 117(3):471.
8Miguel MR, Ramos D, Soriano P, et al. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: A diagnostic dilemma with immunohistochemical evaluation of 2 cases [J]. Int J Surg Pathol, 2007, 15(2):213.
